Showing 3111-3120 of 5621 results for "".
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- Eye Health America Acquires Three Optometric Practices in the Pee Dee Region of South Carolinahttps://modernod.com/news/eye-health-america-acquires-three-optometric-practices-in-the-pee-dee-region-of-south-carolina/2478837/Eye Health America (EHA) has added three optometric practices into its business family: David Hamill, OD, and First Vision Group (FVG); Mark Vinson, OD and Vision Care (VC); and David Johnson, OD and Marlboro Eye Care Associates (MECA). All have been providing eye care in Florence, Marion and Ben
- Breakthrough by Moran Eye Center Scientist, Colleagues Fuels New Line of Disease Researchhttps://modernod.com/news/breakthrough-by-moran-eye-center-scientist-colleagues-fuels-new-line-of-disease-research/2478830/Scientists like the John A. Moran Eye Center’s Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision. But it’s been difficult to study whether giving
- Eyedaptic Augmented Reality Visual Aid Granted Patent to Further Aid Those With Macular Degeneration and Low Visionhttps://modernod.com/news/eyedaptic-augmented-reality-visual-aid-granted-patent-to-further-aid-those-with-macular-degeneration-and-low-vision/2478789/Eyedaptic announced it was recently granted the first out of nine pending patents. Additionally, Eyedaptic launched an Equity Crowdfunding Campaign to increase awareness and introduce their advanced visual aid solution to an expanding list of stakeholders in the eye care and technology communitie
- Smart Contact Lens Targets Vision Improvement for Those With Impairmentshttps://modernod.com/news/smart-contact-lens-targets-vision-improvement-for-those-with-impairments/2478766/A contact lens that operates like a smartphone in the eye was the breakout but not-yet-ready-for-prime-time health tech at Consumer Electronics Show (CES) this year, according to a Medscape report. The device wields computing and imaging p
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- Notal Vision Launches First US Home OCT Longitudinal Study with Patient Self-Operated Devicehttps://modernod.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/Notal Vision announced that it has initiated the first US-based study using its investigational home-based optical coherence tomography (OCT) platform. The study will evaluate the ability of subjects with wet age-rela
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that